<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03817125</url>
  </required_header>
  <id_info>
    <org_study_id>PICI0014</org_study_id>
    <nct_id>NCT03817125</nct_id>
  </id_info>
  <brief_title>Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention</brief_title>
  <acronym>MCGRAW</acronym>
  <official_title>A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parker Institute for Cancer Immunotherapy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seres Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Parker Institute for Cancer Immunotherapy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and tolerability of treatment with oral
      microbiome study intervention (SER-401) or matching placebo in combination with
      anti-programmed cell death 1 (anti-PD-1) therapy (nivolumab) in participants with
      unresectable or metastatic melanoma. The study also intends to assess clinical outcomes, the
      impact of microbiome study intervention administration on the microbiome profile, and its
      association with clinical and immunological outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b, multicenter, randomized, placebo-controlled, blinded study in adult
      participants with anti-PD-1 therapy naïve, unresectable or metastatic melanoma to evaluate
      the safety and tolerability of SER-401, or matching placebo in combination with anti-PD-1
      therapy (nivolumab). Prior to initiating microbiome study intervention and nivolumab,
      participants will undergo an antibiotic or antibiotic placebo treatment lead-in to prime the
      gut microbiome for engraftment of the oral microbiome study intervention. Study intervention
      groups will be assessed for safety, changes in the microbiome, changes in the percentage of
      tumoral CD8 T cells, and antitumor activity. Participants must have measurable disease that
      can be biopsied and consent to baseline and on-treatment biopsies, as well as stool and blood
      biomarker collection throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participants will be randomly assigned in a 2:1 ratio to oral microbiome study intervention or matching placebo. Nivolumab will be administered open-label as standard of care to all groups. Investigators, site personnel, and participants will remain blinded to the assignment of microbiome study intervention throughout the course of the study. Select Sponsor personnel, including but not limited to the Medical Monitor, Clinical Scientists, Biostatistician, and Patient Safety, will be unblinded to treatment assignment for ongoing safety monitoring.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with Adverse Events (AEs)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the engraftment of SER-401 bacteria in microbiome study intervention group relative to placebo.</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) at Weeks 24 and 52</measure>
    <time_frame>Up to week 52</time_frame>
    <description>Defined as complete response (CR) or partial response (PR) as best response by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) at Weeks 24 and 52</measure>
    <time_frame>Up to week 52</time_frame>
    <description>Defined as CR, PR, or stable disease (SD) for ≥ 24 weeks as best response by RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) Progression free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from randomization to date of first documented progression of disease, date of death due to any cause, or date of most recent participant contact that documented progression-free status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival [OS]</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from randomization until death or last contact if still alive at the time of final data collection (after completion of anti-PD-1 therapy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as time from date of documented CR or PR to date of first documented progression of disease, date of death due to any cause, or date of most recent participant contact that documented response (ie, scan date).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the percentage of CD8 cells in tumor tissue from baseline at Cycle 2.</measure>
    <time_frame>At cycle 2 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>SER-401 Matching Placebo/ Nivolumab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will undergo a 4-day lead-in pretreatment with antibiotic placebo, then matching placebo for SER-401 and nivolumab (480 mg) treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SER-401/ Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo a 4-day lead-in pretreatment with antibiotic (vancomycin) to prime the gut microbiome for engraftment of the oral microbiome study intervention, then SER-401 and nivolumab treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for antibiotic</intervention_name>
    <description>Placebo for antibiotic will be administered orally four times a day for 4 days, followed by a 2-3 day washout.</description>
    <arm_group_label>SER-401 Matching Placebo/ Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin pretreatment</intervention_name>
    <description>Vancomycin (125mg) will be administered orally four times a day, followed by a 2-3 day washout.</description>
    <arm_group_label>SER-401/ Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.</description>
    <arm_group_label>SER-401 Matching Placebo/ Nivolumab</arm_group_label>
    <arm_group_label>SER-401/ Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo for SER-401</intervention_name>
    <description>Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.</description>
    <arm_group_label>SER-401 Matching Placebo/ Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER-401</intervention_name>
    <description>Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.</description>
    <arm_group_label>SER-401/ Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant must be willing to provide a baseline stool sample.

          2. Histologically-confirmed Stage IV cutaneous melanoma or Stage III cutaneous, acral or
             mucosal melanoma that is judged inoperable. Participants with a history of uveal
             melanoma are not eligible.

          3. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version
             1.1 (RECIST v1.1; ie, defined as at least 1 lesion that can be accurately measured in
             at least 1 dimension [longest diameter to be recorded] with a minimum size of ≥ 10 mm
             by computerized tomography [CT] scan or caliper measurement on clinical exam or ≥ 20
             mm by chest X-ray).

               1. Malignant lymph nodes must be ≥ 15 mm in short axis when assessed by CT scan to
                  be considered pathologically enlarged and measurable.

               2. Participants must have at least one measurable lesion by RECIST and a separate
                  lesion amenable to biopsy that has not been previously irradiated.

             i. Participants must be willing to undergo a newly-obtained core needle or incisional
             biopsy at baseline (prior to antibiotic or antibiotic placebo administration). Fine
             needle aspiration is not acceptable.

          4. Participants must be willing to undergo tumor biopsy on treatment.

          5. Prior adjuvant or neoadjuvant melanoma therapy is permitted if completed at least 6
             weeks prior to randomization and all related AEs have either returned to baseline or
             stabilized.

               1. Prior anti-CTLA-4 therapy in the adjuvant setting is allowed if completed at
                  least 12 weeks prior to the first dose of anti-PD-1.

               2. Prior BRAF-targeted therapy in the neoadjuvant, adjuvant, or metastatic setting
                  is allowed if completed at least 4 weeks prior to the first dose of anti-PD-1.

        Exclusion Criteria:

          1. Participants who require hemodialysis.

          2. Participants with a history of another cancer in the last 5 years, except for: a)
             curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma
             in situ; c) localized prostate cancer not requiring systemic therapy; and c) other
             primary tumors with no known active disease present that, in the opinion of the
             Investigator and the Sponsor, will not affect participant outcome in the setting of
             the current diagnosis.

          3. Any known, untreated brain metastases. Participants with brain metastases are eligible
             if these have been treated, and provided:

               1. Brain metastases must be stable (image-documented) 4 weeks after completion of
                  treatment for brain metastases and require treatment with less than 10 mg/day
                  prednisone equivalent for at least 2 weeks prior to study intervention
                  administration.

               2. Neurological symptoms should be absent or returned to baseline.

          4. Prior checkpoint inhibitor therapy with anti-PD-1 or anti-PD-L1 in the adjuvant
             setting.

          5. Prior systemic treatment (ie, anticancer chemotherapy, immunotherapy, or
             investigational agents) for unresectable or metastatic melanoma.

             a. Prior BRAF-targeted therapy (ie, BRAF or BRAF-MEK) in the metastatic setting is
             allowed if completed at least 4 weeks prior to the first dose of anti-PD-1.

          6. History of active inflammatory bowel disease (eg, active Crohn's disease or ulcerative
             colitis) with diarrhea OR major gastrointestinal surgery (not including appendectomy
             or cholecystectomy) within 3 months of enrollment (ie, signed informed consent for the
             study), OR any history of total colectomy or bariatric surgery (bariatric surgery
             which does not disrupt the gastrointestinal lumen, ie, restrictive procedures such as
             banding, are permitted).

          7. Any diagnosis of autoimmune disease. Participants with Type I diabetes mellitus,
             hypothyroidism only requiring hormone replacement, adrenal insufficiency on
             replacement dose steroids, skin disorders (such as vitiligo, psoriasis or alopecia)
             not requiring systemic treatment, or conditions not expected to recur in the absence
             of an external trigger are permitted to enroll.

             a. Participants with controlled Type 1 diabetes mellitus on a stable insulin regimen
             may be eligible.

          8. Has a condition requiring systemic treatment with either corticosteroids (&gt; 10 mg
             daily prednisone equivalents) or other immunosuppressive medications within 14 days of
             study intervention administration or has a contrast allergy requiring premedication
             with corticosteroids. Inhaled or topical steroids, and adrenal replacement doses &gt; 10
             mg daily prednisone equivalents are permitted in the absence of active autoimmune
             disease.

          9. Has a transplanted organ or has undergone allogeneic bone marrow transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramy Ibrahim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Parker Institute for Cancer Immunotherapy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the site directly. If there is no contact info,</last_name>
    <phone>please email</phone>
    <email>mcgraw0014@parkerici.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saba Mukarram</last_name>
      <phone>310-231-2181</phone>
      <email>smukarram@theangelesclinic.org</email>
    </contact>
    <investigator>
      <last_name>Omid Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Curran</last_name>
      <phone>617-643-8804</phone>
      <email>rlcurran@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Genevieve Boland, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Maattala</last_name>
      <phone>617-632-3992</phone>
      <email>jennifera_maattala@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Ott, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Martin</last_name>
      <phone>646-888-4339</phone>
      <email>martinn@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Alexander Shoushtari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Cain</last_name>
      <phone>713-792-8874</phone>
      <email>scain@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Isabella C Glitza, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hussein A Tawbi, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lizzy Constantz</last_name>
      <phone>801-587-4568</phone>
      <email>elizabeth.constantz@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Grossman, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT02437487</url>
    <description>NCT02437487: SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT02530385</url>
    <description>NCT02530385: Fecal Microbiota Transplant for Obesity and Metabolism</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT02618187</url>
    <description>NCT02618187: A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER- 287 in Subjects With Mild-to-Moderate Ulcerative Colitis Patients</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT03341143</url>
    <description>NCT03341143: Fecal Microbiota Transplant (FMT) in Melanoma Patients</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT03353402</url>
    <description>NCT03353402: Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT03637803</url>
    <description>NCT03637803: MRx0518 and Pembrolizumab Combination Study</description>
  </link>
  <link>
    <url>http://www.opdivohcp.com/servlet/servlet.FileDownload?file=00Pi000000kLoKcEAK</url>
    <description>Opdivo Immune-Mediated Adverse Reactions Management Guide. Bristol-Myers Squibb Company, 2017</description>
  </link>
  <link>
    <url>http://www.opdivohcp.com/?cid=sem_230964&amp;ovl=isi</url>
    <description>Opdivo (nivolumab) US Prescribing Information (USPI), Aug-2018</description>
  </link>
  <link>
    <url>http://cancerres.aacrjournals.org/content/77/13_Supplement/CT073</url>
    <description>Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038</description>
  </link>
  <reference>
    <citation>Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis. 2015 Feb 4;2(1):ofv004. doi: 10.1093/ofid/ofv004. eCollection 2015 Jan.</citation>
    <PMID>26034755</PMID>
  </reference>
  <reference>
    <citation>Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sondak VK. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10;28(14):2452-9. doi: 10.1200/JCO.2009.27.1627. Epub 2010 Apr 5.</citation>
    <PMID>20368546</PMID>
  </reference>
  <reference>
    <citation>Choi HH, Cho YS. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. Clin Endosc. 2016 May;49(3):257-65. doi: 10.5946/ce.2015.117. Epub 2016 Mar 9. Review.</citation>
    <PMID>26956193</PMID>
  </reference>
  <reference>
    <citation>Dubberke ER, Lee CH, Orenstein R, Khanna S, Hecht G, Gerding DN. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. Clin Infect Dis. 2018 Sep 28;67(8):1198-1204. doi: 10.1093/cid/ciy259.</citation>
    <PMID>29617739</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Ekwueme DU, Guy GP Jr, Li C, Rim SH, Parelkar P, Chen SC. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S133-43. doi: 10.1016/j.jaad.2011.04.036.</citation>
    <PMID>22018062</PMID>
  </reference>
  <reference>
    <citation>Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.</citation>
    <PMID>29097493</PMID>
  </reference>
  <reference>
    <citation>Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013 Mar-Apr;4(2):125-35. doi: 10.4161/gmic.23571. Epub 2013 Jan 18.</citation>
    <PMID>23333862</PMID>
  </reference>
  <reference>
    <citation>Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.</citation>
    <PMID>20525992</PMID>
  </reference>
  <reference>
    <citation>Khanna S, Button JE, Lombardo MJ, Vulic M, Henn MR, Cook DN, Pomerantz RJ, Hohmann EL. Reply to Lagier et al. J Infect Dis. 2017 Jan 1;215(1):162-164. doi: 10.1093/infdis/jiw490. Epub 2016 Oct 20.</citation>
    <PMID>28077592</PMID>
  </reference>
  <reference>
    <citation>Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.</citation>
    <PMID>26027431</PMID>
  </reference>
  <reference>
    <citation>Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, Weese JS, Collins S, Moayyedi P, Crowther M, Ropeleski MJ, Jayaratne P, Higgins D, Li Y, Rau NV, Kim PT. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2016 Jan 12;315(2):142-9. doi: 10.1001/jama.2015.18098.</citation>
    <PMID>26757463</PMID>
  </reference>
  <reference>
    <citation>Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 2016 Dec 15;375(24):2369-2379. Review.</citation>
    <PMID>27974040</PMID>
  </reference>
  <reference>
    <citation>Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 Jan 5;359(6371):104-108. doi: 10.1126/science.aao3290.</citation>
    <PMID>29302014</PMID>
  </reference>
  <reference>
    <citation>McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):987-994. doi: 10.1093/cid/ciy149.</citation>
    <PMID>29562266</PMID>
  </reference>
  <reference>
    <citation>Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015 Jul;149(1):102-109.e6. doi: 10.1053/j.gastro.2015.04.001. Epub 2015 Apr 7.</citation>
    <PMID>25857665</PMID>
  </reference>
  <reference>
    <citation>Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017 Mar 25;389(10075):1218-1228. doi: 10.1016/S0140-6736(17)30182-4. Epub 2017 Feb 15.</citation>
    <PMID>28214091</PMID>
  </reference>
  <reference>
    <citation>Pigneur B, Sokol H. Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail. Mucosal Immunol. 2016 Nov;9(6):1360-1365. doi: 10.1038/mi.2016.67. Epub 2016 Jul 27. Review.</citation>
    <PMID>27461176</PMID>
  </reference>
  <reference>
    <citation>Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR. The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. Gut Microbes. 2017 Nov 2;8(6):574-588. doi: 10.1080/19490976.2017.1353848. Epub 2017 Sep 12. Review.</citation>
    <PMID>28723262</PMID>
  </reference>
  <reference>
    <citation>Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. Erratum in: JAMA. 2016 Jun 14;315(22):2472.</citation>
    <PMID>27092830</PMID>
  </reference>
  <reference>
    <citation>Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.</citation>
    <PMID>25891173</PMID>
  </reference>
  <reference>
    <citation>Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.</citation>
    <PMID>25399552</PMID>
  </reference>
  <reference>
    <citation>Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.</citation>
    <PMID>29097494</PMID>
  </reference>
  <reference>
    <citation>Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9.</citation>
    <PMID>25667295</PMID>
  </reference>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.</citation>
    <PMID>28055103</PMID>
  </reference>
  <reference>
    <citation>Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.</citation>
    <PMID>26541606</PMID>
  </reference>
  <reference>
    <citation>Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin. 2016 Nov 12;66(6):460-480. doi: 10.3322/caac.21352. Epub 2016 May 27. Review.</citation>
    <PMID>27232110</PMID>
  </reference>
  <reference>
    <citation>Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, Ferrante M, Van Assche G, Rutgeerts P, Raes J. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohns Colitis. 2016 Apr;10(4):387-94. doi: 10.1093/ecco-jcc/jjv203. Epub 2015 Oct 29.</citation>
    <PMID>26519463</PMID>
  </reference>
  <reference>
    <citation>Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS One. 2016 Aug 16;11(8):e0161174. doi: 10.1371/journal.pone.0161174. eCollection 2016. Review.</citation>
    <PMID>27529553</PMID>
  </reference>
  <reference>
    <citation>Weingarden A, González A, Vázquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D, Knights D, Unno T, Bobr A, Kang J, Khoruts A, Knight R, Sadowsky MJ. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome. 2015 Mar 30;3:10. doi: 10.1186/s40168-015-0070-0. eCollection 2015.</citation>
    <PMID>25825673</PMID>
  </reference>
  <reference>
    <citation>Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.</citation>
    <PMID>19934295</PMID>
  </reference>
  <reference>
    <citation>Youngster I, Mahabamunuge J, Systrom HK, Sauk J, Khalili H, Levin J, Kaplan JL, Hohmann EL. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 2016 Sep 9;14(1):134. doi: 10.1186/s12916-016-0680-9.</citation>
    <PMID>27609178</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>anti-PD1</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Microbiome</keyword>
  <keyword>SER-401</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

